Trollhattan

• ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signa … Pending
  2024-513778-23-00 5 Colon and rectal cancer tumor stage II-III, tumor with somatic alterat
• Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) Pending
  2025-523476-23-00 4 Tick-Borne Encephalitis (TBE)
• Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer Recruiting
  2022-502221-18-00 6 2025-05-26 Recurrent non-muscle invasive bladder cancer
• Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment Recruiting
  2025-524022-18-00 4 2026-05-22 Multiple myeloma
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 … Recruiting
  2023-508196-36-00 4 2025-05-27 Follicular lymphoma
• A clinical phase IV trial to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in … Recruiting
  2024-511182-10-01 6 2025-05-22 Pediatric cancer
• COMeBAC- COMparison between Bensypenicillin And Cloxacillin treatment in PSSA Recruiting
  2023-506860-15-00 6 2024-06-11 Staphylococcus aureus bacteraemia
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• Alternative antibiotics to multidrug-resistant UTIs Recruiting
  2024-513294-41-00 6 2023-04-17 Urinary tract infection and/or bacteremia caused by extended spectrum
• SACK Recruiting
  2022-501600-10-00 5 2023-02-07 Atrial fibrillation and Chronic Kidney Disease stage 5
• A randomized double-blind clinical trial comparing Hypochlorous Acid and Polyhexamethylene biguanide in treating diabetic foot ulcers Recruiting
  2024-512612-22-00 5 2021-12-09 Diabetic Foot Ulcer
• OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting
  2023-507164-39-00 6 2021-12-01 Induction of labour
• Optimized pharmacologic treatment for broken heart (takotsubo) syndrome Recruiting
  2022-501874-21-00 6 2020-12-15 Takotsubo syndrome
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot … Ended recruitment
  2023-506668-15-00 5 2024-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o … Ended recruitment
  2023-504277-20-00 5 2023-01-30 Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorde
• Ixekizumab Diabetes Intervention Trial (I-DIT) Ended recruitment
  2023-508588-58-00 4 2022-10-25 Diabetes type 1
• Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended recruitment
  2023-509864-96-00 4 2021-12-07 Mantle Cell Lymphoma (MCL)
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma
• A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended recruitment
  2024-517321-99-00 4 2016-08-01 Myeloma multiplex
• An open label, multi-center, Phase IV rollover protocol to evaluate long term safety data Ended recruitment
  2024-515283-31-00 6 2015-07-30 This study is designed to accept patients with varied disease origins,
• Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Ended
  2024-515892-36-00 4 2020-01-01 C3 glomerulopathy
• ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma … Ended
  2022-501138-49-00 4 Follicular Lymphoma

Showing 1–22 of 22 trials